Species differences in the response of liver drug-metabolizing enzymes to (S)-4-O-tolylsulfanyl-2-(4-trifluormethyl-phenoxy)-butyric acid (EMD 392949) in vivo and in vitro

Drug Metabolism and Disposition

Volumn 36, Issue 4, 2008, Pages 702-714

  Richert, Lysiane ^a,b   Tuschl, Gregor ^c   Viollon Abadie, Catherine ^b   Blanchard, Nadège ^b   Bonet, Alexandre ^a   Heyd, Bruno ^e   Halkic, Nermin ^f   Wimmer, Elmar ^d   Dolgos, Hugues ^d,g   Mueller, Stefan O ^c  

^a UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^b KaLy Cell   (France)

^c Merck Serono GmbH   (Germany)

^d MERCK KGAA   (Germany)

^e UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^f LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^g ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

4 O TOLYLSULFANYL 2 (4 TRIFLUOROMETHYLPHENOXY)BUTYRIC ACID; CYTOCHROME P450 2C; CYTOCHROME P450 3A; CYTOCHROME P450 4A; DRUG METABOLIZING ENZYME; EMD 392949; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL CULTURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOG; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INDUCTION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; LIVER METABOLISM; MALE; MONKEY; MONOLAYER CULTURE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; REGULATORY MECHANISM; SPECIES DIFFERENCE; TREATMENT DURATION;

AGED; ANIMALS; BUTYRIC ACID; CELLS, CULTURED; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; LIVER; MACACA FASCICULARIS; MALE; MIDDLE AGED; PPAR ALPHA; RATS; RATS, WISTAR; SPECIES SPECIFICITY;

PRIMATES; RATTUS; RODENTIA;

EID: 41549113856     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.018358     Document Type: Article

References (39)

1. Altschul SF, Gish W, Miller W, Myers EW, and Lipman DJ (1990) Basic local alignment search tool. J Mol Biol 215:403-410.
2. Ammerschlaeger M, Beigel J, Klein KU, and Mueller SO (2004) Characterization of the species-specificity of peroxisome proliferators in rat and human hepatocytes. Toxicol Sci 78:229-240.
3. Bradford N (1976) A rapid and sensitive method for the quantitation ofmicrogram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-253.
4. Castell JV, Jover R, Martinez-Jimenez CP, and Gomez-Lechon MJ (2006) Hepatocyte cell lines: their use, scope and limitations in drug metabolism studies. Expert Opin Drug Metab Toxicol 2:183-212.
5. Coecke S, Ahr H, Blaauboer BJ, Bremer S, Casati S, Castell J, Combes R, Corvi R, Crespi CL, Cunningham ML, et al. (2006) Metabolism: a bottleneck in in vitro toxicological test development. The report and recommendations of ECVAM workshop 54. Altern Lab Anim 34:49-84.
6. Devergne B and Wahli W (1999) Peroxisome proliferator-activated receptor: nuclear control of metabolism. Endocr Res 20:649-688.
7. Dvorak Z, Modriansky M, and Pichard-Garcia L (2003) Colchicine down-regulates cytochrome P450 2B6, 2C8, 2C9 and 3A4 in human hepatocytes by affecting their glucocorticoid receptor-mediated regulation. Mol Pharmacol 64:160-169.
8. Fan LQ, You L, Brown-Borg H, Brown S, Edwards RJ, and Corton JC (2004) Regulation of phase I and phase II steroid metabolism enzymes by PPAR alpha activators. Toxicology 204:109-121.
9. Faucette SR, Hawke RL, LeCluyse EL, Shord SS, Yan B, Laethem RM, and Lindley CM (2000) Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos 28:1222-1230.
10. Faucette SR, Sueyoshi T, Smith CM, Negishi M, LeClusye EL, and Wang H (2006) Differential regulation of hepatic CYP2B6 and CYP3A4 genes by constitutive androstane receptor but not pregnane X receptor. J Pharmacol Exp Ther 317:1200-1209.
11. Goll V, Alexandre E, Viollon-Abadie C, Nicod L, Jaeck D, and Richert L (1999) Comparison of the effect of various peroxisome proliferators on peroxisomal enzyme activities, cell proliferation and apoptosis in rat and human hepatocyte cultures. Toxicol Appl Pharmacol 160:21-32.
12. Harrity T, Farrelly D, Tieman A, Chu C, Kunselman L, Gu L, Ponticiello R, Cap M, Qu F, Shao C, et al. (2006) Muraglitazar, a novel dual (alpha/gamma) peroxisome proliferator-activated receptor activator, improves diabetes and other metabolic abnormalities and preserves beta-cell function in db/db mice. Diabetes 55:240-248.
13. Hewitt NJ, Lechon MJ, Houston JB, Hallifax D, Brown HS, Maurel P, Kenna JG, Gustavsson L, Lohmann C, Skonberg C, et al. (2007) Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab Rev 39:159-234.
14. Johnson EF, Hsu MH, Svas U, and Griffin KJ (2002) Regulation of P450 4A expression by peroxisome proliferator activated receptors. Toxicology 181-182:203-206.
15. LeCluyse EL, Alexandre E, Hamilton GA, Viollon-Abadie C, Coon DJ, Jolley S, and Richert L (2005) Isolation and culture of primary human hepatocytes, in Methods in Cell Biology: Basic Cell Culture Protocols (Helgason CD and Miller CL eds) pp 207-229, Humana Press Inc., Totowa, NJ.
16. LeCluyse EL, Madan A, Hamilton G, Carroll K, Dehaan R, and Parkinson A (2000) Expression and regulation of cytochrome P450 enzymes in primary cultures of human hepatocytes. J Biochem Mol Toxicol 14:177-188.
17. Lowry OH, Rosenbrough NJ, Farr AL, and Randall JJ (1951) Protein measurement with the folin phenol reagent. J Biol Chem 193:265-275.
18. Madan A, Graham RA, Carroll KM, Mudra DR, Burton LA, Krueger LA, Downey AD, Czerwinski M, Forster J, Ribadeneira MD, et al.(2003) Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab Dispos 31:421-431.
19. Okita RT, Clark JE, Okita JR, and Masters BS (1991) Omega- and (omega-1)-hydroxylation of eicosanoids and fatty acids by high-performance liquid chromatography. Methods Enzymol 206:432-441.
20. Parkinson A (2001) Biotransformation of xenobiotics, in Casarett and Doull's Toxicology. The Basic Science of Poisons (Klaassen CD ed) pp 133-224, McGraw Hill, New York.
21. Perrone CE, Shao L, and Williams GM (1998) Effect of rodent hepatocarcinogenic peroxisome proliferators on fatty acyl-CoA oxidase, DNA synthesis, and apoptosis in cultured human and rat hepatocytes. Toxicol Appl Pharmacol 150:277-286.
22. Prueksaritanont T, Richards KM, Qin Y, Strong-Basalyga K, Miller A, Li C, Eisenhandler R, and Carlini EJ (2005) Comparative effects of fibrates on drug metabolizing enzymes in human hepatocytes. Pharmacol Res 22:71-78.
23. Raucy JL, Lasker J, Ozaki K, and Zoleta V (2004) Regulation of CYPE1 by ethanol and palmitic acid and CYP4A11 by clofibrate in primary cultures of human hepatocytes. Toxicol Sci 79:233-241.
24. Reschly EJ and Krasowski MD (2006) Evolution and function of the NR1I nuclear hormone receptor subfamily (VDR, PXR, and CAR) with respect to metabolism of xenobiotics and endogenous compounds. Curr Drug Metab 7:349-365.
25. Richert L, Alexandre E, Lloyd T, Orr S, Abadie-Viollon C, Patel R, Kingston K, Berry D, Dennison A, Heyd H, et al. (2004) Tissue collection, transport and isolation procedures required to optimize human hepatocyte isolation from waste liver surgical resections. Liver Int 24:371-378.
26. Richert L, Binda D, Hamilton G, Viollon-Abadie C, Alexandre E, Bigot-Lasserre D, Bars R, Coassolo P, and LeCluyse E (2002) Evaluation of the effect of culture configuration on morphology, survival, antioxidant status and metabolic capacities of cultured rat hepatocytes. Toxicol In Vitro 16:89-99.
27. Richert L, Lamboley C, Viollon-Abadie C, Grass P, Hartmann N, Laurent S, Heyd B, Mantion G, Chibout SD, and Staedtler F (2003) Effects of clofibric acid on mRNA expression profiles in primary cultures of rat, mouse and human hepatocytes. Toxicol Appl Pharmacol 191:130-146.
28. Richert L, Liguori MC, Viollon-Abadie C, Halkic N, Heyd B, Mantion G, and Waring JF (2006) Gene expression in human hepatocytes in suspension after isolation is similar to the liver of origin, is not affected by hepatocyte cold storage and cryopreservation but is strongly changed after hepatocyte plating. Drug Metab Dispos 34:870-879.
29. Richert L, Price S, Chesné C, Maita K, and Carmichael N (1996) Comparison of the induction of hepatic peroxisome proliferation by the herbicide oxadiazon in vivo in rats, mice and dogs and in vitro in rat and human hepatocytes. Toxicol Appl Pharmacol 141:35-43.
30. Robertson P, Decory HH, Madan A, and Parkinson A (2000) In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil. Drug Metab Dispos 28:664-671.
31. Shaban Z, El-Shazly S, Kimura MIK, Kazusaka A, and Fujita S (2004) PPARα-dependent modulation of hepatic CYP1A by clofibric acid in rats. Arch Toxicol 78:496-507.
32. Shaban Z, Soliman M, El-Shazly S, El-Bohi K, Abdelazeez A, Kehelo K, Kim HS, Muzandu K, Ishizuka M, Kazusaka A, et al. (2005) AhR and PPARalpha: antagonistic effects on CYP2B and CYP3A, and additive inhibitory effects on CYP2C11. Xenobiotica 35:51-68.
33. Silva JM, Morin PE, Day SH, Kennedy BP, Payette P, Rushmore T, Yergey JA, and Nicoll-Griffith DA (1998) Refinement of an in vitro cell model for cytochrome P450 induction. Drug Metab Dispos 26:490-496.
34. Small GM, Burdett K, and Connock MJ (1985) A sensitive spectrophotometric assay for peroxisomal acyl-CoA oxidase. Biochem J 227:205-210.
35. Staels B and Fruchart JC (2005) Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 54:2460-2470.
36. Sugatani J, Yamakawa K, and Tonda E (2004) The induction of human UDP-glucuronosyltransferase 1A1 mediated through a distal enhancer module by flavonoids and xenobiotics. Biochem Pharmacol 67:989-1000.
37. Tuschl G and Mueller SO (2006) Effects of cell culture conditions on primary rat hepatocytes: cell morphology and differential gene expression. Toxicology 218:205-215.
38. Viollon-Abadie C, Bigot-Lassère D, Nicod L, Carmichael N, and Richert L (2000) Effects of model inducers on thyroxine UDP-glucuronosyl transferase activity in vitro in rat and mouse hepatocyte cultures. Toxicol In Vitro 14:505-512.
39. Waxman DJ (1999) P450 gene induction by structurally diverse xenochemicals: central role of nuclear receptors CAR, PXR, and PPAR. Arch Biochem Biophys 369:11-23.